Indian Priority Pathogen List (IPPL): WHO & DBT
The objectives of the IPPL are to
• guide the prioritization of research on AMR, including incentives and funding;
• help align R&D priorities with Indian public health needs; and
• support India’s leadership in containment of antibiotic resistant bacteria
The IPPL shall be useful for policy initiatives to incentivise basic science and advanced R&D by
both public funding agencies and the private sector investing in new antibiotics.
CRITICAL PRIORITY
Enterobacteriaceae
(Klebsiella pneumoniae and Escherichia coli)
Carbapenem – R
Tigecycline – R
Colistin – R
Non-fermenting bacteria
(Acinetobacter baumannii and Pseudomonas aeruginosa)
Carbapenem – R
Colistin – R
HIGH PRIORITY
Staphylococcus aureus
MRSA, hVISA
Daptomycin – NS
Linezolid – R
Enterococcus species
Vancomycin – R
Linezolid – R
Daptomycin – NS
Salmonella species
(Typhoidal and Non-typhoidal)
Azithromycin – NS
Third generation cephalosporins – NS
Carbapenem – NS
MEDIUM PRIORITY
Streptococcus pneumoniae
Cephalosporin – R
Fluoroquinolones – R
Linezolid – R
Staphylococcus, coagulase-negative
Vancomycin – R
Linezolid – R
Shigella species
Third generation cephalosporins – R
Azithromycin – R
Haemophilus influenzae
Third generation cephalosporin – NS
Carbapenem – NS
Neisseria meningitidis
Fluoroquinolones – NS
Third generation cephalosporins – NS
The following steps were followed for developing the IPPL:
- Desk review of biomedical literature on key antibiotic resistant bacteria in the Indian
context; - Analysis of available data and information on bacterial drug resistance mechanisms;
- Prepare draft list of prioritized antibiotic-resistant bacteria and key resistance
mechanisms; and - Review and finalization of the list of top-10 bacterial drug-resistant pathogens
Suggested readings:
About Author
